Elevance Health, Inc. (ELV) Stock Price & Analysis
Elevance Health, Inc. (ELV) rose 1.50% to USD 424.43 as of June 9, 2026 at 22:42 UTC, according to Nexqual real-time market data.
ELV last closed at USD 418.15; the session ranged USD 418.65–426.66 on volume of 1,379,996 shares. Market capitalization is $92.17B, with a 52-week range of USD 273.71–426.66 (NYQ). Source: Nexqual, June 9, 2026 at 22:42 UTC.
Key Statistics (as of June 9, 2026 at 22:42 UTC)
| Price | USD 424.43 |
|---|---|
| Change | ▲ 1.50% (up) |
| Previous Close | USD 418.15 |
| Open | USD 420.2 |
| Day Range | USD 418.65 – 426.66 |
| 52-Week Range | USD 273.71 – 426.66 |
| Volume | 1,379,996 shares |
| Market Cap | $92.17B |
| Exchange | NYQ |
Technical Analysis (ELV)
Nexqual's technical model rates ELV "BUY" based on 5 bullish and 3 bearish signals across 124 daily candles, as of June 9, 2026 at 22:42 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 74.38 (overbought) |
| vs SMA50 | Above (USD 361.04) |
| MACD | 14.01 (positive) |
Analyst Ratings (ELV)
Wall Street analysts rate ELV "Buy" based on 21 analysts, with a mean price target of USD 415.81 (range USD 331–498), per Nexqual as of June 9, 2026 at 22:42 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 21 |
| Mean Target | USD 415.81 |
| High Target | USD 498 |
| Low Target | USD 331 |
| Buy / Hold / Sell | 14 / 8 / 0 |
Earnings (ELV)
| Next Earnings Date | 2026-07-16 |
|---|---|
| EPS Estimate | USD 6.2 |
| Revenue Estimate | $48.63B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 12.58 vs est 10.81 ▲ beat |
| 2025-12-31 | USD 3.33 vs est 3.09 ▲ beat |
| 2025-09-30 | USD 6.03 vs est 4.94 ▲ beat |
| 2025-06-30 | USD 8.84 vs est 8.92 ▼ miss |
Source: Nexqual, June 9, 2026 at 22:42 UTC.
Financials & Fundamentals (ELV)
| Total Revenue | $200.42B |
|---|---|
| Revenue Growth (YoY) | +2.60% |
| Gross Margin | +25.89% |
| Operating Margin | +5.30% |
| Profit Margin | +2.62% |
| ROE | +12.09% |
| Debt / Equity | 72.3 |
| Current Ratio | 1.48 |
| Total Cash | $37.07B |
| Total Debt | $31.84B |
| Free Cash Flow | $4.30B |
Source: Nexqual, June 9, 2026 at 22:42 UTC.
Financial Health Score (ELV)
Nexqual rates Elevance Health, Inc.'s overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 22:42 UTC.
| Growth | Solid — Revenue +13% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 26%, operating 5% |
| Balance Sheet | Solid — $37.1B cash vs $31.8B debt, net cash position |
| Cash Flow | Mixed — FCF $4.30B, slim 2.2% margin |
| Efficiency | Mixed — ROE 12%, ROA 4.0% |
Ownership (ELV)
| Insider Ownership | +0.18% |
|---|---|
| Institutional Ownership | +93.46% |
| Shares Outstanding | 217.16M |
| Float | 216.71M |
| Short % of Float | +3.14% |
Source: Nexqual, June 9, 2026 at 22:42 UTC.
Leadership (ELV)
Elevance Health, Inc. is led by Gail Koziara Boudreaux (age 64), President, CEO & Director, per Nexqual as of June 9, 2026 at 22:42 UTC.
| President, CEO & Director | Gail Koziara Boudreaux (age 64) |
|---|---|
| Executive VP & CFO | Mark Bradley Kaye (age 45) |
| EVP and President of Commercial & Specialty Health Benefits | Charles Morgan Kendrick (age 59) |
| Vice President of Investor Relations | Nathan Allen Rich |
| Senior Vice President of Public Affairs | Julie Goon |
Major Backers & Investors (ELV)
Notable institutional backers of Elevance Health, Inc. include Wellington Management, Sanders Capital, LLC, Artisan Partners Limited Partnership, according to Nexqual as of June 9, 2026 at 22:42 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Wellington Management | 3.79% |
| Sanders Capital, LLC | 2.71% |
| Artisan Partners Limited Partnership | 2.36% |
| Invesco | 2.22% |
| Harris Associates L.P. | 2.21% |
| First Eagle Funds-First Eagle Global Fund | 1.31% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 19.35% |
| BlackRock | 10.47% |
| State Street | 5.95% |
| Geode Capital | 2.39% |
Source: Nexqual, June 9, 2026 at 22:42 UTC.
From Elevance Health, Inc.'s Latest SEC 10-K Filing (filed 2026-02-06)
Key Strengths & Strategy (as disclosed to the SEC)
- Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States.
- The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other.
- It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits.
- The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MOH | Molina Healthcare Inc | USD 203.06 | ▲ 6.39% |
| HUM | Humana Inc. | USD 363.18 | ▲ 3.74% |
| CNC | Centene Corporation | USD 66.21 | ▲ 6.22% |
| CI | The Cigna Group | USD 295 | ▲ 1.91% |
| HCA | HCA Healthcare, Inc. | USD 374.9 | ▲ 0.74% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:42 UTC. This page is informational and not investment advice.